Drug Profile


Alternative Names: DPP IV inhibitor - Pfizer; PF-00734200; PF-734,200; SatRx

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; SatRx
  • Class Antihyperglycaemics; Pyrrolidines; Small molecules
  • Mechanism of Action CD antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 08 Jun 2016 Registered for Type-2 diabetes mellitus in Russia (PO) - First global approval
  • 01 Jun 2016 Preregistration for Type-2 diabetes mellitus in Russia (PO)
  • 05 Jul 2012 Gosogliptin licensed to SatRx worldwide (excluding China)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top